Navigating the Latest Hepatitis B Virus Reactivation Guidelines.

Area of Science:

• Hepatology and Infectious Diseases
• Clinical Practice Guidelines
• Immunosuppression Management

Background:

• Hepatitis B virus (HBV) infection affects over 254 million globally.
• Immunosuppressive therapies (ISTs) are increasingly used, raising the risk of HBV reactivation (HBVr).
• HBVr incidence ranges from 15-50% in HBsAg-positive individuals on IST, exceeding 75% post-stem cell transplant.

Purpose of the Study:

• To compare the latest clinical guidelines from the American Gastroenterological Association (AGA), European Association for the Study of the Liver (EASL), and Asian Pacific Association for the Study of the Liver (APASL) on HBV reactivation.
• To highlight similarities and differences in predicting and managing HBVr during IST.
• To provide practical guidance for clinicians facing complex and sometimes conflicting recommendations.

Main Methods:

• Narrative review of current guidelines (AGA 2025, EASL 2025, APASL 2021).
• Comparative analysis of risk stratification, prophylaxis effectiveness, and antiviral recommendations.
• Focus on practical implications for clinical decision-making.

Main Results:

• All guidelines stratify HBVr risk into high (>10%), moderate (1-10%), and low (<1%).
• Prophylaxis effectiveness is risk-dependent; cost-effective for high-risk, potentially beneficial for moderate-risk, and generally not advised for low-risk patients.
• Entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF) are effective and economically viable for high-risk patients, with safety and insurance influencing selection.

Conclusions:

• Guidelines provide a framework for managing HBVr risk during IST.
• Risk stratification and prophylaxis are key components of management.
• Antiviral selection involves balancing efficacy, safety (renal/bone toxicity), and cost.